Lineage Cell Therapeutics — Third Quarter 2026 Earnings Summary

Lineage Cell Therapeutics reported a net income of $4.2 million for the third quarter of 2026, driven primarily by a non-cash gain from the fair value remeasurement of warrant liabilities. The company acquired NeuroAirmid Therapeutics, adding the HUNT1 clinical-stage cell therapy candidate for Huntington's Disease to its pipeline, and secured a U.S. patent for its AlloSCOPE 5D manufacturing technology. Financial results showed total revenues of $1.4 million and operating expenses of $8.8 million, with cash and marketable securities totaling $45.2 million expected to fund operations through the second quarter of 2028. Key program updates include the advancement of the ReSonance hearing loss therapy into the second year of its collaboration with William Demant Invest and the initiation of preclinical testing for the COR1 corneal endothelial disease program.